Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The value of BCMA-targeting agents in treating patients with penta-refractory multiple myeloma

Shebli Atrash • 27 Sep 2023
IMS 2023
Multiple Myeloma

Shebli Atrash, MD, Levine Cancer Institute, Charlotte, NC, discusses the results of a retrospective study evaluating the outcomes of patients with penta-refractory multiple myeloma treated with BCMA-targeting immunotherapies over standard of care (SOC) approaches. Patients treated with BCMA-based immunotherapy demonstrated an increase in progression-free survival (PFS), highlighting the value of BCMA as a target in this disease. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Shebli Atrash

0:48
The prognostic value of bone marrow Ki-67 in NDMM
Shebli Atrash • 27 Sep 2023
1:33
Ruxolitinib plus carfilzomib & dexamethasone for patients with carfilzomib-refractory myeloma
Shebli Atrash • 27 Sep 2023
1:47
Phase I trial evaluating belantamab mafodotin plus KRd in patients with multiple myeloma
Shebli Atrash • 27 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals